Dog /

Breed profile · FDA CVM July 2026 extract

Spaniel - Boykin adverse-event record

Adverse-event filings for Spaniel - Boykin (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.

#121 of 510
by report volume (all breeds)
740
FDA CVM reports on file
1.6%
death-coded share of reports
#267 of 275
by death-coded share (≥50 reports)

How the 740 reports break down

By recorded gender -- every report on file for Spaniel - Boykin, no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 84 63 42 21 0 2019 2020 2021 2022 2023 2024 2025 2026 Reports filed Death-coded reports
Annual report volume for Spaniel - Boykin drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Spaniel - Boykin ranks #121 of 510 by total reports (740) and #267 of 275 by death-coded share (1.6%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#121
This breed, reports of 510
#267
This breed, death share of 275

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Spaniel - Boykin has 740 reports now versus 725 in that prior snapshot: 15 more (2.1%).

Report change
+15
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Spaniel - Boykin changes

Total Reports

740

High report volume

Deaths Reported

12

of 740 reports

Death-coded share of reports

1.6%

Lowest death-coded share

Avg Age at Report

4.3 yr

16.7 kg avg weight

Breed Safety Scorecard

C+ (62/100)

A weighted composite across 4 of 4 dimensions, each benchmarked against every tracked breed with at least 200 reports (n=185). Dimensions with insufficient data drop out and their weight redistributes to the rest, so a missing input never silently deflates the score.

Death rate A+
1.6%

Share of reports coded as a fatality

Euthanasia rate A+
1.1%

Share of reports resulting in euthanasia

Full recovery rate F
24.2%

Share of reports coded "Recovered/Normal"

5-year trend F
+75%

Change in annual report volume over the last 5 complete years

Death-Coded Outcome Share

Spaniel - Boykin death-coded reports 1.6%
Cross-breed median

1.6% of 740 spaniel - boykin reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Where Spaniel - Boykin's death-coded share sits among indexed breeds

Death-coded share of FDA CVM reports, breeds with ≥50 reports (July 2026 extract)

2% 3rd percentile Higher share than 3% of 275 indexed breeds

5%–10%: 1 indexed breeds (0%). This entry sits in this band. 20%–25%: 2 indexed breeds (1%). Above this entry. 25%–30%: 3 indexed breeds (1%). Above this entry. 30%–35%: 4 indexed breeds (1%). Above this entry. 35%–40%: 5 indexed breeds (2%). Above this entry. 40%–45%: 6 indexed breeds (2%). Above this entry. 45%–50%: 3 indexed breeds (1%). Above this entry. 50%–55%: 7 indexed breeds (3%). Above this entry. 55%–60%: 7 indexed breeds (3%). Above this entry. 60%–65%: 21 indexed breeds (8%). Above this entry. 65%–70%: 11 indexed breeds (4%). Above this entry. 70%–75%: 15 indexed breeds (5%). Above this entry. 75%–80%: 13 indexed breeds (5%). Above this entry. 80%–85%: 11 indexed breeds (4%). Above this entry. 85%–90%: 12 indexed breeds (4%). Above this entry. 90%–95%: 12 indexed breeds (4%). Above this entry. 95%–100%: 142 indexed breeds (52%). Above this entry. Spaniel - Boykin 5% 100% every breed with ≥50 FDA reports, bucketed by value

Each bar is a band; taller bars hold more indexed breeds. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source FDA Center for Veterinary Medicine, openFDA adverse event extract (PlainBreed) · July 2026 extract

This histogram uses the same ≥50-report cohort as the highest death-coded share ranking. A higher share means more of this breed's reported events were death-coded, not a mortality rate for living animals.

Average weight at time of report: 16.7 kg (36.8 lbs)

Top Reported Reactions

Lack of efficacy (endoparasite) - heartworm 153
Vomiting 129
Lack of efficacy (endoparasite) - hookworm 72
INEFFECTIVE, HEARTWORM LARVAE 54
Emesis 42
Lethargy (see also Central nervous system depression in 'Neurological') 39
Lack of efficacy - NOS 36
Diarrhoea 32

Most Referenced Drugs

Milbemycin Oxime + Spinosad 147
Ivermectin + Pyrantel As Pamoate Salt 127
Moxidectin 89
Pyrantel Pamoate;Sarolaner 67
Milbemycin Oxime + Praziquantel 53
Afoxolaner 44
Spinosad 30
Fluralaner 13.64% 12-Week Chew 23

Outcome Breakdown

Ongoing
238 (34.0%)
Outcome Unknown
237 (33.9%)
Recovered/Normal
179 (25.6%)
Recovered with Sequela
34 (4.9%)
Euthanized
8 (1.1%)
Died
4 (0.6%)

Gender Distribution

Male 384 (51.9%)
Female 348 (47.0%)
Unknown 7 (0.9%)
Mixed 1 (0.1%)

Reports by Year

Year Reports Trend
2010 21
2011 31
2012 33
2013 32
2014 28
2015 35
2016 41
2017 42
2018 42
2019 47
2020 48
2021 48
2022 64
2023 68
2024 66
2025 84
2026 10

Spaniel - Boykin: low death-coded share in the FDA CVM extract

Signature read: Spaniel - Boykin's 1.6% death-coded share is in the lower third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Spaniel - Boykin sits at #121 of 510 by report volume among all breeds and #102 of 298 among dog breeds, with 740 reports and 12 (1.6%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #267 of 275. Mean age at report: 4.3 years, average weight 16.7 kg (36.8 lbs).

Top reported signs: Lack of efficacy (endoparasite) - heartworm (153), Vomiting (129), Lack of efficacy (endoparasite) - hookworm (72). Most-referenced drug: Milbemycin Oxime + Spinosad (147 reports), followed by Ivermectin + Pyrantel As Pamoate Salt (127) and Moxidectin (89).

Outcome coding on 700 status-recorded reports is dominated by Ongoing (34.0%). Annual submissions ranged 10-2,026 across 17 years on file.

Dog Breeds With a Similar Report Volume

Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.

Nationwide breeds with similar profiles

High-volume peer sets for Spaniel - Boykin drawn from openFDA outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).

Similar death-coded share

Nearest other-species breeds with ≥50 reports (1.6% death-coded here).

Similar average weight

Nearest other-species breeds by reported average weight (16.7 kg here).

What to do with this dog

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Spaniel - Boykin?
There are 740 adverse event reports involving Spaniel - Boykin in the FDA database, of which 12 were death-coded (1.6% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Spaniel - Boykin ranks #121 of 510 by report volume among all breeds PlainBreed indexes (#102 of 298 among dog breeds).
Where does Spaniel - Boykin sit among other breeds in PlainBreed's corpus?
According to FDA CVM report volume, Spaniel - Boykin is #121 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Dog, it is #102 of 298. Among breeds with at least 50 reports, its death-coded share ranks #267 of 275 (same cohort as highest-death-rate). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Spaniel - Boykin?
The most commonly reported adverse reactions for Spaniel - Boykin are Lack of efficacy (endoparasite) - heartworm (153 reports), Vomiting (129 reports), Lack of efficacy (endoparasite) - hookworm (72 reports), INEFFECTIVE, HEARTWORM LARVAE (54 reports), Emesis (42 reports).
What drugs are most frequently associated with Spaniel - Boykin adverse events?
The drugs most frequently referenced in Spaniel - Boykin adverse event reports are Milbemycin Oxime + Spinosad (147 reports), Ivermectin + Pyrantel As Pamoate Salt (127 reports), Moxidectin (89 reports), Pyrantel Pamoate;Sarolaner (67 reports), Milbemycin Oxime + Praziquantel (53 reports).
What is the average age of Spaniel - Boykin in adverse event reports?
The average age of Spaniel - Boykin at the time of adverse event reports is 4.3 years, with an average weight of 16.7 kg (36.8 lbs).

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Spaniel - Boykin (Dog), extract as of July 2026 extract. 740 reports · 12 death-coded (1.6% of reports, not a mortality rate) · #121 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →